Table 1.
List of studies reporting the development of c-miRNA-based biomarkers diagnostic for lung cancer.
| Authors | PubMed ID | miRNA (n) | AUC | Sample Type | LDCT |
|---|---|---|---|---|---|
| Boeri et al. [46] | 21300873 | 13 | 0.88 | Plasma | Yes |
| Sozzi et al. [14] | 24419137 | 24 | - a | Plasma | Yes |
| Bianchi et al. [9] | 21744498 | 34 | 0.89 | Serum | Yes |
| Montani et al. [13] | 25794889 | 13 | 0.85 | Serum | Yes |
| Wozniak et al. [41] | 25965386 | 24 | 0.78 b | Plasma | No |
| Shen et al. [47] | 21864403 | 3 | 0.86 | Plasma | No |
| Lin et al. [48] | 28580707 | 3 | 0.87 | Plasma | No |
| Chen et al. [49] | 21557218 | 10 | 0.97 | Serum | No |
| Wang et al. [42] | 26629532 | 5 | 0.82 | Serum | No |
| Ying et al. [43] | 32943537 | 5 | 0.91–0.97 | Serum | No |
| Zhu et al. [50] | 27093275 | 4 | 0.97 c | Serum | No |
| Nadal et al. [51] | 26202143 | 4 | 0.99 | Serum | No |
| Asakura et al. [44] | 32193503 | 2 | 0.99 | Serum | No |
| Fehlmann et al. [45] | 32134442 | 15 | - d | Blood | No |
The number of miRNA (n) in each diagnostic signature is reported together with the performance (AUC, i.e., area under curve) and the type of biospecimen where biomarkers were derived (Serum or Plasma). LDCT, studies which performed validation of biomarkers on actual LD-CT screening trials (Yes). a Sensitivity, 88% and a specificity of 80%; b Predicted performance when applied to independent samples. c miRNAs combined with carcinoembryonic antigen (CEA). d Sensitivity, 82.8%, and a specificity of 93.5%. PubMed identifiers (PubMed ID) are reported to allow retrieving cited publications.